Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor

Roxana G. Burciu, Edward Ofori, Priyank Shukla, Ofer Pasternak, Jae Woo Chung, Nikolaus R. McFarland, Michael S. Okun, David E. Vaillancourt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson's disease (PD). Data in animal models of PD suggest that chronic administration of rasagiline is associated with structural changes in the substantia nigra, and raise the question whether the structure and function of the basal ganglia could be different in PD patients treated chronically with rasagiline as compared with PD patients not treated with rasagiline. Here, we performed a retrospective cross-sectional magnetic resonance imaging (MRI) study at 3 T that investigated nigrostriatal function and structure in PD patients who had taken rasagiline before testing (∼8 months), PD who had not taken rasagiline before testing, and age-matched controls. The two PD groups were selected a priori to not differ significantly in age, sex, disease duration, severity of symptoms, cognitive status, and total levodopa equivalent daily dose of medication. We evaluated percent signal change in the posterior putamen during force production using functional MRI, free-water in the posterior substantia nigra using diffusion MRI, and performance on a bimanual coordination task using a pegboard test. All patients were tested after overnight withdrawal from antiparkinsonian medication. The rasagiline group had greater percent signal change in the posterior putamen, less free-water in the posterior substantia nigra, and better performance on the coordination task than the group not taking rasagiline. These findings point to a possible chronic effect of rasagiline on the structure and function of the basal ganglia in PD. Hum Brain Mapp 37:2894–2903, 2016.

Original languageEnglish (US)
Pages (from-to)2894-2903
Number of pages10
JournalHuman Brain Mapping
Volume37
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Monoamine Oxidase Inhibitors
Monoamine Oxidase
Parkinson Disease
Water
Substantia Nigra
Putamen
Basal Ganglia
Magnetic Resonance Imaging
Antiparkinson Agents
rasagiline
Neurobehavioral Manifestations
Diffusion Magnetic Resonance Imaging
Levodopa
Amphetamine
Animal Models
Brain

Keywords

  • free-water diffusion MRI
  • nigrostriatal regions
  • Parkinson's disease
  • rasagiline
  • task-based fMRI

ASJC Scopus subject areas

  • Anatomy
  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology

Cite this

Burciu, R. G., Ofori, E., Shukla, P., Pasternak, O., Chung, J. W., McFarland, N. R., ... Vaillancourt, D. E. (2016). Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. Human Brain Mapping, 37(8), 2894-2903. https://doi.org/10.1002/hbm.23213

Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. / Burciu, Roxana G.; Ofori, Edward; Shukla, Priyank; Pasternak, Ofer; Chung, Jae Woo; McFarland, Nikolaus R.; Okun, Michael S.; Vaillancourt, David E.

In: Human Brain Mapping, Vol. 37, No. 8, 01.08.2016, p. 2894-2903.

Research output: Contribution to journalArticle

Burciu, RG, Ofori, E, Shukla, P, Pasternak, O, Chung, JW, McFarland, NR, Okun, MS & Vaillancourt, DE 2016, 'Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor', Human Brain Mapping, vol. 37, no. 8, pp. 2894-2903. https://doi.org/10.1002/hbm.23213
Burciu, Roxana G. ; Ofori, Edward ; Shukla, Priyank ; Pasternak, Ofer ; Chung, Jae Woo ; McFarland, Nikolaus R. ; Okun, Michael S. ; Vaillancourt, David E. / Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. In: Human Brain Mapping. 2016 ; Vol. 37, No. 8. pp. 2894-2903.
@article{0d12ac8ddebd4e9d94c16541e82f98e3,
title = "Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor",
abstract = "Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson's disease (PD). Data in animal models of PD suggest that chronic administration of rasagiline is associated with structural changes in the substantia nigra, and raise the question whether the structure and function of the basal ganglia could be different in PD patients treated chronically with rasagiline as compared with PD patients not treated with rasagiline. Here, we performed a retrospective cross-sectional magnetic resonance imaging (MRI) study at 3 T that investigated nigrostriatal function and structure in PD patients who had taken rasagiline before testing (∼8 months), PD who had not taken rasagiline before testing, and age-matched controls. The two PD groups were selected a priori to not differ significantly in age, sex, disease duration, severity of symptoms, cognitive status, and total levodopa equivalent daily dose of medication. We evaluated percent signal change in the posterior putamen during force production using functional MRI, free-water in the posterior substantia nigra using diffusion MRI, and performance on a bimanual coordination task using a pegboard test. All patients were tested after overnight withdrawal from antiparkinsonian medication. The rasagiline group had greater percent signal change in the posterior putamen, less free-water in the posterior substantia nigra, and better performance on the coordination task than the group not taking rasagiline. These findings point to a possible chronic effect of rasagiline on the structure and function of the basal ganglia in PD. Hum Brain Mapp 37:2894–2903, 2016.",
keywords = "free-water diffusion MRI, nigrostriatal regions, Parkinson's disease, rasagiline, task-based fMRI",
author = "Burciu, {Roxana G.} and Edward Ofori and Priyank Shukla and Ofer Pasternak and Chung, {Jae Woo} and McFarland, {Nikolaus R.} and Okun, {Michael S.} and Vaillancourt, {David E.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/hbm.23213",
language = "English (US)",
volume = "37",
pages = "2894--2903",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor

AU - Burciu, Roxana G.

AU - Ofori, Edward

AU - Shukla, Priyank

AU - Pasternak, Ofer

AU - Chung, Jae Woo

AU - McFarland, Nikolaus R.

AU - Okun, Michael S.

AU - Vaillancourt, David E.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson's disease (PD). Data in animal models of PD suggest that chronic administration of rasagiline is associated with structural changes in the substantia nigra, and raise the question whether the structure and function of the basal ganglia could be different in PD patients treated chronically with rasagiline as compared with PD patients not treated with rasagiline. Here, we performed a retrospective cross-sectional magnetic resonance imaging (MRI) study at 3 T that investigated nigrostriatal function and structure in PD patients who had taken rasagiline before testing (∼8 months), PD who had not taken rasagiline before testing, and age-matched controls. The two PD groups were selected a priori to not differ significantly in age, sex, disease duration, severity of symptoms, cognitive status, and total levodopa equivalent daily dose of medication. We evaluated percent signal change in the posterior putamen during force production using functional MRI, free-water in the posterior substantia nigra using diffusion MRI, and performance on a bimanual coordination task using a pegboard test. All patients were tested after overnight withdrawal from antiparkinsonian medication. The rasagiline group had greater percent signal change in the posterior putamen, less free-water in the posterior substantia nigra, and better performance on the coordination task than the group not taking rasagiline. These findings point to a possible chronic effect of rasagiline on the structure and function of the basal ganglia in PD. Hum Brain Mapp 37:2894–2903, 2016.

AB - Rasagiline is a monoamine oxidase type B inhibitor that possesses no amphetamine-like properties, and provides symptomatic relief in early and late stages of Parkinson's disease (PD). Data in animal models of PD suggest that chronic administration of rasagiline is associated with structural changes in the substantia nigra, and raise the question whether the structure and function of the basal ganglia could be different in PD patients treated chronically with rasagiline as compared with PD patients not treated with rasagiline. Here, we performed a retrospective cross-sectional magnetic resonance imaging (MRI) study at 3 T that investigated nigrostriatal function and structure in PD patients who had taken rasagiline before testing (∼8 months), PD who had not taken rasagiline before testing, and age-matched controls. The two PD groups were selected a priori to not differ significantly in age, sex, disease duration, severity of symptoms, cognitive status, and total levodopa equivalent daily dose of medication. We evaluated percent signal change in the posterior putamen during force production using functional MRI, free-water in the posterior substantia nigra using diffusion MRI, and performance on a bimanual coordination task using a pegboard test. All patients were tested after overnight withdrawal from antiparkinsonian medication. The rasagiline group had greater percent signal change in the posterior putamen, less free-water in the posterior substantia nigra, and better performance on the coordination task than the group not taking rasagiline. These findings point to a possible chronic effect of rasagiline on the structure and function of the basal ganglia in PD. Hum Brain Mapp 37:2894–2903, 2016.

KW - free-water diffusion MRI

KW - nigrostriatal regions

KW - Parkinson's disease

KW - rasagiline

KW - task-based fMRI

UR - http://www.scopus.com/inward/record.url?scp=84978924154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978924154&partnerID=8YFLogxK

U2 - 10.1002/hbm.23213

DO - 10.1002/hbm.23213

M3 - Article

C2 - 27089850

AN - SCOPUS:84978924154

VL - 37

SP - 2894

EP - 2903

JO - Human Brain Mapping

JF - Human Brain Mapping

SN - 1065-9471

IS - 8

ER -